In May 2021, AKIPress reported Uzbekistan plans to use CoronaVac. In October 2021, Singapore included CoronaVac in its National Vaccination Programme for people aged 18 and over who are ineligible for mRNA vaccines due to allergies or serious adverse reactions after the first dose. Africa In March, Benin received 203,000 doses of CoronaVac and started vaccinations on 29 March prioritizing healthcare workers, people over 60, and those with co-morbidities. In April, Botswana received 200,000 doses of CoronaVac as a donation and purchased an additional 200,000 doses to be used in the vaccination program. In March, Djibouti received 300,000 doses of CoronaVac. In April, Egypt approved emergency use of CoronaVac. In April, Guinea received 300,000 doses of CoronaVac which it had purchased. In April, Libya received 150,000 doses of CoronaVac from Turkey. In April, Somalia received 200,000 doses of CoronaVac. In July, South Africa approved CoronaVac for emergency use, and was expected to receive 2.5 million doses shortly. In April, Togo received 200,000 doses of CoronaVac. In March, Tunisia's Ministry of Health approved marketing authorization for CoronaVac and the first 200,000 doses arrived on 25 March. In March, Zimbabwe approved emergency use and the first 1 million doses arrived on 30 March. Europe In March, Albania launched its vaccination campaign using mainly CoronaVac, a week after securing 1 million doses from Turkey. By June, Northern Cyprus received 190,000 doses donated by Turkey. In March, Bosnia received 30,000 doses donated by Turkey. In June, North Macedonia received 30,000 doses donated by Turkey and another 500,000 doses it purchased. In March, Ukraine granted approval for use of CoronaVac. Ukrainian Pharmaceutical Company Lekhim has an agreement to deliver 5 million doses. 1.7 million doses had been delivered by June. In April, Moldova purchased 400,000 doses of CoronaVac. South America In Brazil, São Paulo governor João Doria signed a $90 million contract with Sinovac in September to receive the initial 46 million doses of CoronaVac. The price for CoronaVac was announced to be US$10.3 (about R$59). In January, Brazil announced it would obtain 100 million total doses. On 17 January, Brazil's health regulatory agency Anvisa approved emergency use of CoronaVac. In early February, Brazil said it intends to buy an additional 30 million doses on top of existing 100 million doses. A total of 39.7 million doses had been delivered by early April. In October, Chile signed an agreement to purchase 20 million doses of